Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
RVP Catalyst Timeline
Dated clinical, regulatory and corporate events for Retractable Technologies, Inc.
Past FDA Catalysts and PDUFA Decisions
How RVP actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Drug Pipeline Intelligence
No drug pipeline
Retractable Technologies, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every RVP program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| SHAW THOMAS JDirector, Officer (PRESIDENT AND CEO), 10% Owner | Buy | 5,731 15,831,222 held | $0.77 | 11/14/2025 |
Hedge Fund 13F Activity
Hedge Funds invested in RVP
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in RVP for Q2 2026. | ||||
Ownership Trends
RVP Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How RVP ranks across every disease it competes in
RVP News
Retractable Technologies, Inc. Results for the Periods Ended September 30, 2026
Retractable Technologies, Inc. reported total net sales of $14.1 million for Q3 2026, up from $10.1 million in the same period last year. However, the company also faced an operating loss of $4.1 million. For the first nine months of 2026, net sales reached $28.5 million, slightly down from $28.8 million in 2025.
Read more →Retractable Technologies, Inc. Declares Dividends to Series II and III Class B Preferred Stock Shareholders
Retractable Technologies, Inc. has announced the declaration of dividends for its Series II and III Class B Convertible Preferred Stock. The total dividends amount to $57,611.25, with $39,050.00 allocated to Series II and $18,561.25 to Series III. These dividends will be paid on October 22, 2026, covering the period from July 1, 2026, to September 30, 2026.
Read more →Retractable Technologies, Inc. Supports Senator Blackburn’s ONSHORE Manufacturing Act
Retractable Technologies, Inc. has expressed its support for Senator Marsha Blackburn's ONSHORE Manufacturing Act. This legislation aims to enhance domestic production of essential medical supplies by offering tax incentives for U.S. manufacturing. The act is expected to stimulate investments in advanced manufacturing equipment and facility upgrades.
Read more →Retractable Technologies, Inc. Results for the Periods Ended June 30, 2026
Retractable Technologies, Inc. reported a decline in net sales for the second quarter of 2026, totaling $7.2 million, down from $10.4 million in the same period last year. The company also experienced an operating loss of $5.1 million, consistent with the previous year. For the first half of 2026, net sales were $14.4 million, compared to $18.7 million in 2025, indicating ongoing financial challenges.
Read more →RETRACTABLE TECHNOLOGIES, INC. RESULTS FOR THE PERIOD ENDED MARCH 31, 2026
Retractable Technologies, Inc. reported total net sales of $7.2 million for the first quarter of 2026, a decline from $8.3 million in the same period last year. The company experienced an operating loss of $6.2 million compared to $4.7 million the previous year, influenced by increased operating expenses and a significant reduction in domestic sales. Despite a rise in international sales driven by EasyPoint needle sales, overall revenues fell due to decreased selling prices and a negative gross margin. Additionally, the workforce was reduced by approximately 16% to save costs.
Read more →Retractable Technologies, Inc. Announces Workforce Reduction
Retractable Technologies, Inc. has announced a 16% workforce reduction aimed at saving approximately $2.2 million in annual costs. This decision is part of the company's strategy to enhance domestic production and reduce reliance on imports from China, particularly in light of tariff impacts. While the move is expected to improve efficiency, it also involves one-time separation payments for affected employees.
Read more →RETRACTABLE TECHNOLOGIES, INC. ANNOUNCES
Retractable Technologies, Inc. has announced a significant workforce reduction of about 16%, aimed at saving approximately $2.2 million in annual costs. This move is part of the company's strategy to enhance domestic manufacturing capabilities and mitigate reliance on Chinese imports, largely influenced by tariffs. Although the reduction will help cut costs, it also brings about one-time separation payments to affected workers and continues the company's dependence on imports for certain products.
Read more →RETRACTABLE TECHNOLOGIES, INC. REPORTS
Retractable Technologies, Inc. reported a 15.8% increase in revenues for the year 2025, reaching approximately $38.3 million. Significant growth in international sales, particularly for EasyPoint needles, contributed to this rise. However, the company also faced high operating costs and incurred losses from operations totaling $21.2 million, similar to the previous year’s results. The ongoing impact of tariffs, particularly a 120% rate on imported products from China, creates uncertainty for future operations and financial stability.
Read more →RETRACTABLE TECHNOLOGIES, INC. DECLARES DIVIDENDS TO SERIES II AND III CLASS B PREFERRED STOCK SHAREHOLDERS
Retractable Technologies, Inc. has announced the declaration of dividends for its Series II and III Class B Preferred Stock shareholders, amounting to $39,050.00 and $18,561.25 respectively. These dividends, accruing at $1.00 per share per annum, cover the period from October 1 to December 31, 2025, and are set to be paid on January 20, 2026, to shareholders recorded by January 10, 2026. This announcement highlights the company's ongoing commitment to providing returns to its investors amidst its operational initiatives in safety medical products.
Read more →Retractable Technologies, Inc. Receives Innovative Technology Designation from Vizient for EasyPoint Blood Collection Tube Holder with Needle
Retractable Technologies, Inc. has announced that its EasyPoint Blood Collection Tube Holder with Needle has received an Innovative Technology designation from Vizient. This recognition highlights the product's potential to enhance patient and healthcare worker safety by reducing needlestick injuries. The device is designed for ease of use and efficiency, demonstrating the company's commitment to innovation in healthcare.
Read more →RETRACTABLE TECHNOLOGIES, INC. RESULTS FOR THE PERIODS ENDED SEPTEMBER 30, 2025
Retractable Technologies, Inc. reported total net sales of $10.1 million and an operating loss of $3.7 million for Q3 2025, reflecting a modest improvement compared to the prior year's results. The company continues to face challenges due to high tariffs on imported products, which have materially affected its operational costs. Despite the difficulties, there has been a reduction in overall operating losses, and international revenues saw an increase. Moving forward, efforts to shift production to domestic facilities are ongoing to mitigate tariff impacts.
Read more →Retractable Technologies Welcomes Congressional Leaders to Highlight Texas Innovation and U.S. Supply Chain Readiness
Retractable Technologies, Inc. hosted Texas congressional leaders to showcase its efforts in enhancing domestic manufacturing of medical devices. The visit emphasized the company's commitment to protecting healthcare workers and strengthening the U.S. supply chain, with over $138 million invested since the COVID-19 pandemic. CEO Thomas Shaw highlighted the importance of collaboration between policy and industry.
Read more →RETRACTABLE TECHNOLOGIES, INC. RESULTS FOR THE PERIODS ENDED JUNE 30, 2025
Retractable Technologies, Inc. reported total net sales of $10.4 million for Q2 2025, up from $6.0 million in Q2 2024, but also recorded a higher operating loss of $5.1 million. Tariffs imposed on imports from China continue to heavily affect the company's financial performance, prompting a shift toward more U.S.-based production. Moreover, sales of the EasyPoint needle contributed positively to revenues, but a decrease in average selling price due to product mix changes was noted. The company also reported a net loss for the first six months of the year totaling $10.6 million, including an unrealized loss on investments of $5.6 million, although they received a $1.9 million settlement in the second quarter.
Read more →RETRACTABLE TECHNOLOGIES, INC. ANNOUNCES REDUCTION IN ITS MANUFACTURING WORKFORCE
Retractable Technologies, Inc. has announced a 12.4% reduction in its manufacturing workforce, aiming to save about $1.6 million in annual costs. This move is part of the company's strategy to enhance domestic production while facing challenges posed by tariffs on imported products from China. The decision also involves one-time separation payments to affected workers, highlighting the company's need to balance costs with operational efficiency. The future remains uncertain regarding U.S. trade policy and its effects on the company's import capabilities.
Read more →RETRACTABLE TECHNOLOGIES, INC. RESULTS FOR THE PERIOD ENDED MARCH 31, 2025
Retractable Technologies, Inc. reported total net sales of $8.3 million for Q1 2025, marking an increase from $7.6 million in Q1 2024. However, the company experienced a higher operating loss of $4.7 million, attributed to rising tariffs and increased production costs, which also contributed to a significant unrealized loss on investments. Domestic sales represented a strong 89.6% of total revenues, with unit sales up by 18.9%, although average selling prices faced pressure due to shifts in product mix. The ongoing challenges from tariffs are anticipated to impact future profitability.
Read more →RETRACTABLE TECHNOLOGIES, INC. ANNOUNCES REDUCTION IN WORKFORCE
Retractable Technologies, Inc. has announced a 7% reduction in its workforce, aiming to save around $1.6 million in annual wages and benefits. The company plans to enhance its U.S. manufacturing capabilities, decreasing reliance on products produced in China due to tariffs. While this move may provide some long-term financial benefits, the company faces immediate costs associated with separation payments and uncertainty related to future trade policies.
Read more →